Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide

Phase 2

Completed

• Conditions: Ovarian Hyperstimulation Syndrome
• Interventions: Drug: Norprolac

• Registration Number: NCT00329693
• Lead Sponsor: Ferring Pharmaceuticals

Brief Summary

Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.

Detailed Description

No data to be entered.

Study Timeline

• Study First Submitted: 2006-05-23
• Study First Submitted QC: 2006-05-24
• Study First Posted: 2006-05-25
• Study Start: 2006-06
• Primary Completion: 2007-08
• Study Completion: 2008-05
• Status Verified: 2011-05
• Last Update Submitted: 2011-05-18
• Last Update Posted: 2011-05-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 182

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
3	Norprolac	Daily Tablets Dosing
4	Norprolac	Daily Tablets Dosing
1	Norprolac	Daily Tablets Dosing
2	Norprolac	Daily Tablets Dose

Primary Outcome Measures

Name	Time	Method
OHSS	41 days after hCG injection

Trial Locations

Locations (7)

IVI Bilbao, Paseo Landabarri, 1; 🇪🇸 Leioa-Bizkaia, Spain

IVI Sevilla, Avda. República Argentina, 58; 🇪🇸 Sevilla, Spain

IVI Barcelona, Ronda General Mitre, 14; 🇪🇸 Barcelona, Spain

IVI Murcia, Navegante Macías del Poyo, 5, Edificio Delfín-Barrio La Flota; 🇪🇸 Murcia, Spain

IVI Madrid, Santiago de Compostela, 88; 🇪🇸 Madrid, Spain

IVI Valencia, Plaza de la Policía Local, 3; 🇪🇸 Valencia, Spain

IVI Vigo, Plaza Francisco Fernández del Riego, 7 (Plaza Elíptica); 🇪🇸 Vigo (Pontevedra), Spain